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1. INTRODUCTION 
Infection includes several bacteriological, morphological, biochemical, and 
immunological processes between pathogenic bacteria, host, and commensal 
bacteria.  
Pathogenic bacteria are defined by their inherent ability to cross anatomical 
barriers due to specific virulence factors, inhabit tissue sites, breach host 
defences that ordinarily limit the survival, or replication of commensal bacteria 
(Falkow, 2006). The distinction between the pathogen and the commensal is not 
always easy as some commensals may cause disease in certain conditions, 
whereas some pathogens can persist without any disease symptoms. 
In the majority of infections the interaction between the bacteria and the 
host`s immune system eradicates the invading bacteria. If some pathogens 
survive, they cause persistent infection (Young et al., 2002¸ Rhen et al., 2003). 
This may lead to recurring infections with high epidemiological burden and/or 
morbidity of patients or carriage of the particular microbe. 
Salmonella Typhi causes enteric fever in many parts of the developing 
world, especially in Asia and North Africa (Andrews-Polymenis et al., 2010), 
despite the decline in the overall incidence of typhoid fever due to a specific 
typhoid fever control program, economic development, and improved 
sanitation. 
In treatment of infectious diseases, the discovery of antibiotics more than 70 
years ago significantly increased the survival of patients suffering from bacterial 
infections. Today we have met problems concerning antibiotic resistance, e.g. 
multidrug resistance and resistance to nalidixic acid and fluoroquinolone among 
Salmonella serotypes responsible for typhoid fever have been reported (Chau et 
al., 2007). Until recently it was evident that the antibiotic resistance is due to 
overuse of antibiotics that enables the migration of resistance-carring plasmids 
and integrons. However, D’Costa and colleagues demonstrated with targeted 
metagenomic analyses of ancient DNA from 30000-year-old Beringian per-
mafrost sediments that antibiotic resistance is a natural phenomenon that 
predates use of antibiotics (D’Costa et al., 2011). Though antibiotic treatment is 
targeted against bacterial pathogens it also alters the gut microbial ecology, 
resulting in selective removal of commensals and changes in the colonization 
resistance. The antibiotic-induced disturbances in microbiota composition are 
mostly temporary, returning to its original composition within 2 months 
(Gerritsen et al., 2011). Administration of indigenous non-pathogenic bacteria 
is an option for restoring the colonization resistance and microbiota 
composition.  
Lactobacillus spp. strains belong to the category of organisms classified as 
generally regarded as safe for food and medical application (FAO/WHO, 2002). 
Probiotics are defined as live microorganisms which, when administered in 
adequate numbers result in a health benefit for the host. In clinical trials the 
consumption of probiotic food containing different lactic acid bacteria has 
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shown several scientifically established and/or clinically proven health effects 
in preventing particular infections and non-infectious disorders (Minocha, 2009; 
Kullisaar et al., 2003; Songisepp et al., 2004; Mikelsaar, Zilmer et al., 2009; 
Floch et al., 2011). However, there are few studies showing the mechanisms of 
the beneficial effect of different probiotics in experimental Salmonella 
infections (Ashara et al., 2010). 
 We have developed a mouse model of persistent Salmonella Typhimurium 
infection with granulomas that resembles Salmonella Typhi infection in 
humans. Our aim was to test the microbiological, morphological, biochemical 
and immunological effect of the probiotic Lactobacillus fermentum ME-3 on 
the Salmonella Typhimurium persistent infection and to clarify the impact of 
the probiotic Lactobacillus plantarum Inducia in murine model. 
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2. REVIEW OF LITERATURE 
2.1. Essence of persistent infection  
Persistent infection is a specific phase in the pathogenesis of infection rather 
than a fortuitous imbalance in the host–pathogen interaction (Rhen et al., 2003). 
It represents the evolved selection for balancing host and microbial interests, 
resulting in an equilibrium that is long-term but not necessarily stable forever 
(Blazer et al., 2007). From the microbial perspective, persistent infection is 
essential for microbial survival in nature (Monack, 2012). Some pathogenic 
bacteria are capable of maintaining infections in mammalian hosts even in the 
presence of inflammation, specific antimicrobial mechanisms, and adaptive 
immune response giving rise to persistent infection. The persistent infection can 
manifest as acute or chronic disease or can be clinically asymptomatic with the 
potential to be reactivated. For instance, Salmonella Typhi causes systemic 
typhoid fever that involves the colonization of the reticuloendothelial system 
(Monack et al., 2004). 
 
 
2.1.1. Persisters  
The essence of persistent infection may be associated with persister cells. 
Despite the early discovery of persisters by Bigger already in 1944, several 
aspects of persisters are still obscure.  
Persisters are dormant variants of regular cells that form stochastically in 
microbial populations and are highly tolerant to antibiotics (Dorr et al., 2009, 
Lewis, 2010). Dormant cells have a global slowdown of metabolic processes 
and do not divide (Jayaraman and Wood, 2008). The production of persisters 
depends on growth stage: it starts in the early exponential, increases in the mid-
exponential and reaches a maximum of 1% of cells in the stationary phase 
(Keren et al., 2004). Persisters pre-exist in microbial population prior to the 
addition of antibiotics (Balaban et al., 2004). 
Persister cells constitute a small fraction of the population. They are 
transiently refractory to killing, without having acquired resistance through 
genetic modification (Keren et al., 2004; Fauvart et al., 2011). The microbes 
that survive antibiotic treatment are able to give rise to a population sensitive to 
treatment, and the next microbial population again contains a small proportion 
of persister cells. This discriminates persister cells from resistant mutants. 
While resistant mutants are stable with inheritable properties, persistence is a 
reversible microbial phenomenon (Fauvart et al., 2011). 
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2.1.2. CWDB and L-forms 
Under certain conditions bacteria can spontaneously or by induction, lose part 
or all of their cell wall resulting in osmosis-sensitive cells known as cell wall 
deficient bacteria (CWDB). CWDB-s that are capable of specific “fried egg” 
growth on specialized solid media are termed L-forms (Elliott and Lambert, 
2001). 
Despite the discovery of L-form bacteria already in 1935, the molecular 
mechanisms underlying L-form formation and survival have remained obscure. 
L-form formation and survival is associated with pathways and genes involved 
in cell envelope stress, DNA repair, iron homeostasis, outer membrane 
biogenesis, and drug efflux/ABC transporters (Glover et al., 2009). These 
findings suggest a relationship between L-forms and persisters. It has been 
suggested that the usage of antibiotics may generate CWDB. For instance, beta-
lactams and glycopeptides damage bacteria by inhibiting cell wall murein 
synthesis and CWDB are generated before the bacteria die. They have an 
increased ability to uptake DNA by transformation (Woo et al., 2003; 
Onwuamaegbu et al., 2005; Allan et al., 2009). 
 
 
2.2. Persistence and the immune response 
The location of bacteria inside the host cell during persistent infection is crucial 
for its success as a pathogen. Intracellular compartment is relatively safe, if 
bacteria can avoid phagolysosomal fusion as it protects bacteria from immune 
recognition and serum mediated extracellular killing by the host. It has been 
demonstrated earlier that although majority of the bacteria are intracellular in 
Salmonella persistence model of mice, some bacteria may still be located in the 
extracellular compartment (Eswarappa, 2009). Persistent microbes have 
successful strategies to thwart host responses sufficiently to gain a niche. Many 
microbial adaptations have been recognized, involving stealth, antigenic 
variation, and immune response. The known mechanisms of persistence in 
different microbes may vary, e.g. in S. Typhi infection the low expression of 
stimuli for innate responses and in Escherichia coli K1 the molecular mimicry 
have been described (Rhen et al., 2003). 
Moreover, in persistent infections the modifications of intra-vacular 
environment of the cell through reduced surface antigen presentation or the 
control of apoptotic pathways are involved. Some bacteria can modify the 
structure of Toll-like receptors (TLR) binding components, for example, 
Salmonella modify their lipid A composition under different growth conditions 
(Rhen et al., 2003). This seemingly complicates the recognition of the pathogen 
and its clearance by immune mechanisms. Recently it was demonstrated that to 
subvert the immune system Salmonella secrets the protein SseI into dendritic 
cells (DC), which normally play a role in immune activation (Ruby and 
Monack, 2011). The bacterial protein interferes with the migration of infected 
4 
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cells to lymphoid tissues by specifically binding to the cell-migration regulator. 
This prevents normal DC migration, limits presentation of Salmonella antigens 
and naive T-cell priming, and thereby inhibits adaptive immunity (McLaughlin 
et al., 2009). 
 
 
2.3. Infections due to S. Typhi and S. Typhimurium 
2.3.1. Taxonomy 
Salmonella is a genus of the family Enterobacteriaceae. According to con-
temporary classification, the genus Salmonella contains only two species, Sal-
monella bongori and Salmonella enterica, but there are more than 2,500 
serotypes of S. enterica due to diverse surface structures of antigens: somatic 
O antigens, the carbohydrate component of lipopolysaccharide (LPS), and 
flagellar H antigens (Andrews-Polymenis et al., 2010). According to the current 
CDC nomenclature system, the full taxonomic designation of Salmonella 
enterica subspecies enterica serotype Typhimurium can be abbreviated as 
Salmonella Typhimurium and similarly S. Typhi.  
A major virulence factor of Salmonella enterica is LPS, and strains with 
reduced LPS expression show poor growth under stress conditions and express 
lowered virulence (Netea et al., 2009). Salmonella sp. can modify their lipid A 
composition under different growth conditions (Rhen et al., 2003), thus 
changing the structure of TLR binding components and becoming un-
recognizable by innate immune mechanisms. 
Different serotypes of Salmonella enterica are responsible for human 
diseases ranging from gastroenteritis to systemic infections. 
 
 
2.3.2. Pathogenesis of S. Typhi infection 
S. enterica Typhi, the etiologic agent of typhoid fever, infects only humans. 
After oral ingestion of a facultative intracellular S. Typhi, it enters the host 
through microfold (M) cells, which are specialized epithelial cells that sample 
intestinal antigens and transport them to lymphoid cells in the underlying 
Peyer’s patches (PP), specialized lymphoid tissue in the small intestine (Jones et 
al., 1994). After penetration through the epithelial barrier, the phagocytes in 
lamina propria ingest S. Typhi. In order for the infection to extend beyond the 
intestinal mucosa, facultatively intracellular S. Typhi is able to survive and 
replicate in macrophages and thus elude the adaptive immune response (Haraga 
et al., 2008). S. Typhi pathogenity island 7 encodes functions for the production 
and export of the Vi-capsular polysaccharide antigen. The latter is important in 
evading detection of S. Typhi by TLR-4 (Monack 2012). Tissue DCs take up 
microbial antigens; migrate to regional lymph nodes, and present processed 
microbial antigens to naïve CD4 T cells. S. Typhi secretes protein SseI into DCs 
(Ruby and Monack 2011). This prevents normal dendritic-cell migration, limits 
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presentation of Salmonella antigens and naive T-cell priming, and thereby 
inhibits adaptive immunity (McLaughlin et al., 2009). 
The activated CD4 T cells leave the lymph node and migrate to the focus of 
the infection, secreting soluble mediators. At the same time, inflammatory 
phagocytes are attracted to the site of microbial invasion in a process mediated 
by cytokines causing up-regulation of adhesion molecules on leukocytes and 
endothelial cells (Nix et al., 2007; Silva-Herzog and Detweiler, 2008). S. Typhi 
reaches bloodstream and spreads to the reticuloendothelial system, including 
spleen, liver and bone marrow. Following the accumulation and activation of 
macrophages by Th-1 cytokines INF-γ, IL-12 and TNF-α, the inflammatory 
lesion may take a granulomatous form.  
There are several possibilities for the outcome of S. Typhi infection. 
Approximately 5% of the diseased persons with acute typhoid fever progress to 
an asymptomatic chronic infection. They will suffer from life-long carriage of 
S. Typhi in the gallbladder from where bacteria reach intestines via the bile 
duct, with periodical excretion in stools. These individuals intermittenly shed 
the pathogen into community sewers and thereby serve as a reservoir for 
dissemination to naïve hosts (Parry et al., 2002). For example, Mary Mallone 
(“bloody Mary”), the first identified healthy typhoid carrier, infected at least 57 
people in New York City before she was confined to lifelong quarantine in 1907 
(Tischler and McKinney, 2010).  
Recently, a correlation between the presence of gallstones and S. Typhi 
carriage was demonstrated. Namely, S. Typhi forms bile-mediated biofilms on 
human gallstones and cholesterol coated surfaces which facilitate the 
gallbladder  colonization (Crawford et al., 2010). Furthermore, the carriers of 
S. Typhi are at risk of developing malignancies in the gastric and the 
hepatobiliar tract (Blaser and Kirschner, 2007). It has been demonstrated that 
significantly high Vi-antigen positivity (29.4%) was observed in patients with 
gallbladder carcinoma (Shukla et al., 2000). 
 
2.3.2.1. Granuloma formation 
The formation of granulomas is a response to chronic inflammatory stimuli 
either of infectious origin (e.g. intracellular microorganisms) or inert material 
(e.g. silica). It is a nodular organized aggregation of mononuclear inflammatory 
cells or a collection of modified macrophages surrounded by a fibrotic rim of 
lymphocytes containing multinucleated giant cells. Granulomas associated with 
infection are commonly understood to be a protective form of delayed-type 
hypersensitivity that leads to the control of the expansion of infection (Sneller, 
2002).  
Microscopically, typhoid lesions consist predominantly of histiocytes, 
lymphocytes, and plasma cells. The typhoid nodules may occur in several 
organs, e.g. the bone marrow, liver, spleen, and in the ileum or mesenteric 
lymph nodes (Bharadwaj et al., 2009). 
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2.3.3. S. Typhimurium infection 
As S. Typhi is restricted to humans, there are no suitable animal models with 
the particular microbe. In order to study the pathogenesis of typhoid fever 
pathogenesis, S. Typhimurium has been used in a murine model of systemic 
infection mimicking persistence observed in S. Typhi carriers (Monack et al., 
2004; Andrews-Polymenis et al., 2010). In humans, opposite to S. enterica 
serovar Typhi, S. enterica serovar Typhimurium does not reach beyond the 
lamina propria and therefore causes self-limiting gastroenteritis and requires 
treatment only in immunosuppressed patients. The infection in mice resembles 
typhoid fever-like systemic infection in humans (Hudault et al., 1997; Monack 
et al., 2004). Similarly, after colonization and invasion of the ileum of mice, S. 
Typhimurium proliferates within the reticuloendothelial system, incl. liver and 
spleen (Thygesen et al., 2000).  
S. Typhi and S. Typhimurium share many of the virulence factors important 
for gastroenteritis, including flagella. The difference is in about 10% of their 
genes, including mutations in over 200 of S. Typhi genes. Interestingly, most of 
the genes involved in intestinal colonization identified in S. Typhimurium are 
inactivated in S. Typhi (Sabbagh et al., 2010). 
 
 
2.4. Oxidative stress  
Oxidation is a gain of oxygen or a loss of electrons, whereas reduction is a loss 
of oxygen or a gain in electrons. Oxidative stress (OxS) is a serious imbalance 
between the generations of reactive oxygen species and antioxidant protection 
in favour of the former, causing excessive oxidative damage (Halliwell, 2011). 
Oxidative stress is a disruption of redox signaling and control (Jones, 2006). 
OxS is considered to play a pivotal role in the pathogenesis of aging and 
several degenerative diseases, atherosclerosis, cardiovascular diseases, type 2 
diabetes, and cancer (Masella et al., 2005). S. Typhimurium-mediated intestinal 
infection is accompanied by an increased generation of reactive oxygen species 
(ROS), which may induce the lipid peroxidation of the enterocyte membrane, 
thereby leading to a loss of cell viability (Mehta et al., 1998). Though the 
cellular damage favours the generalisation of the infection, the role of OxS in 
the development of persistent infection process needs to be clarified. 
 
 
2.4.1. Pro-oxidants  
Pro-oxidants are products of normal cellular metabolism. They are either free 
radicals of reactive oxygen species (ROS) or reactive non-radical particles 
(H2O2, HOCl, O3) with either beneficial or deleterious influence. 
Beneficial effects of ROS occur at low/moderate concentrations and involve 
physiological roles in energy production, in phagocytosis, in intercellular 
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signalling systems, and in cell growth. Besides, ROS can be generated as a 
result of intracellular metabolism of foreign compounds, toxins or drugs by 
cytochrome P450, mono-oxygenases, or due to exposure to environmental 
factors, such as excessive iron salts or UV radiation (Masella et al., 2005).  
At high concentrations, ROS can be important mediators of damage to cell 
structures, nucleic acids, lipids and proteins (Valko et al., 2007).  
Thus, abnormal formation of the reactive species leads to the damage of 
lipids, proteins, nucleic acids and carbohydrates of cells and tissues, and causes 
an imbalance in the pro-oxidants/antioxidants system. 
 
 
2.4.2. Lipid peroxidation  
Lipid peroxidation involves a chain reaction where free radicals remove 
electrons from the lipids of membranes to surrounding cells and organelles such 
as mitochondria, lysosomes, and peroxisomes (Halliwell and Gutterridge, 1999, 
Gutteridge and Halliwell, 2010). This affects polyunsaturated fatty acids 
(PUFAs), which are responsible for the maintenance of physiologically 
important membrane properties, including fluidity and permeability. 
Peroxidation products of PUFAs, such as malonedialdehyde (MDA) and 
alkenals, are also mutagenic and cytotoxic and can damage membrane proteins. 
Increased production of ROS also oxidizes unsaturated fatty acids of cell 
membranes and produces lipid hydroperoxides by initiating a chain reaction 
(Halliwell and Chirico, 1993). This leads to changes in cell membranes which 
result in tissue damage (Baker and He, 1991). 
Still, the role of LPO in persistent infections is obscure and needs further 
investigation.  
 
 
2.4.3. Antioxidants 
By definition, antioxidant is “any substance that delays, prevents or removes 
oxidative damage to a target molecule” (Gutteridge and Halliwell, 2010). 
Defence mechanisms against free radical-induced oxidative stress involve 
antioxidants. Enzymatic antioxidant defences include superoxide dismutase, 
glutathione peroxidase, catalase and heme oxygenase. Non-enzymatic anti-
oxidants are glutathione (GSH), ascorbic acid (vitamin C), α-tocopherol (vita-
min E), carotenoids, and flavonoids, blood albumine, uric acid, and bilirubin 
(Halliwell, 2011).  
 
2.4.3.1. Glutathione 
Glutathione is a cysteine-containing tripeptide that exists either in the reduced 
(GSH) or in the oxidized (GSSG) form. Under normal cellular redox conditions, 
the major portion is in reduced form and is distributed in mammals’ red blood 
5 
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cells, liver, spleen, pancreas, kidneys, eyes and intestinal cells, while GSSG 
cellular level is maintained at less than 1% of the total glutathione via rapid 
reduction back to GSH by glutathione reductase (Zilmer et al. 2005). 
GSH has several biological functions. It is the major non-enzymatic 
antioxidant of intracellular redox homeostasis; is involved in the restoration of 
of thiol groups of proteins and coenzyme A, and is required for the stabilization 
of cell membranes, for the synthesis of proteins, nucleic acids, leukotriens and 
prostaglandins (Masella et al., 2005, Zilmer et al. 2005). In the presence of 
oxidative stress, GSH concentration rapidly decreases while GSSG increases 
due to the reduction of peroxides or as a result of free radical scavenging. The 
redox state of the cell is linked to iron and copper redox couple and is 
maintained within strict physiological limits. It has been suggested that iron 
regulation ensures depletion of free intracellular iron; however, in vivo, under 
stress conditions, e.g. infection, an excess of superoxide releases “free iron” 
from iron-containing molecules (Peran et al., 2006; Halliwell, 2009; Niki, 
2010).  
 
 
2.5. Immunity in infection 
The immune response is a redox regulated process; the activation of T 
lymphocytes is significantly enhanced by ROS or by a shift in intracellular 
glutathione redox state (Halliwell, 2011). Vertebrates have evolved two 
complementary systems to detect and clear pathogens: the innate and the 
adaptive immune system. Persistence is established after an acute infection 
period involving activation of both the innate and acquired immune system 
(Young et al., 2002). Persistent infection may continue for a long time due to 
constant modulation of the immune system and/or the microbe. The primary 
function of the immune system is to protect the host from the harmful insults of 
microorganisms. The pattern-recognition receptors (PRRs) are expressed by 
many cell types, including macrophages, monocytes, DCs, neutrophils, and 
epithelial cells.They allow the early detection of pathogens directly at the site of 
the infection (Medzhitov and Janeway, 2002). PRRs recognize conserved 
microbial signatures termed pathogen-associated molecular patterns (PAMPs) 
(Janeway, 1992).  
Toll-like receptors (TLRs) are the most intensely studied of PRRs. So far, 
there are 10 members of the human and 13 members of the mouse TLR family 
that have been identified. TLR1-TLR10 are similar in humans and mice, 
although TLR10 is not functional in mice due to a retroviral insertion. TLRs 
11–13 are not present in humans. Thus, despite some species-specific receptors, 
most members are similar in mammals. Once activated by PAMPs, the TLRs 
induce different signalling cascades leading to the activation of the transcription 
factors and interferon-regulatory factor.  
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TLR activation results in the production of antimicrobial peptides, 
inflammatory cytokines and chemokines, e.g. TNF-α, IL-1 and costimulatory 
adhesion molecules, as well as in the upregulation of major histocompatibility 
complexes (MHCs). Besides TLR, two other families of PRRs have been 
described: the NLRs (NOD-like receptors) and the RLHs (RIG-like helicases). 
Unlike TLRs, these families consist of soluble proteins that give the cytoplasm 
signs of intracellular pathogens (Martinon et al., 2009).  
Although both arms of the immune system (innate and adaptive) have 
distinct functions, there is interplay between these systems (i.e., components of 
the innate immune system influence the adaptive immune system and vice 
versa). 
Opsonisation of the respective microbes facilitates phagocytosis by 
phagocytes. During phagocytosis, small peptides bind to MHC class II proteins. 
The adaptive immune system exerts highly specific responses to microbes by 
producing antibodies from B cells or through the generation of killer or helper T 
lymphocytes, resulting in life-long immunological memory (Yamamoto and 
Takeda, 2010). T and B lymphocytes recognize the antigen specific sites. B 
lymphocytes recognize a membrane, proliferate and differentiate into antibody 
producing plasma cells. T lymphocytes are divided into: T-helper, regulatory, 
and cytotoxic cells (Mileti et al., 2009). Two types of T helper cells are 
produced in the thymus, the Th1 cells that help the CD8+ pre-cytotoxic cells to 
differentiate into cytotoxic T cells, and Th2 cells that help B cells differentiate 
into plasma cells, which secrete antibodies. Activated Tc cells are involved in 
destruction of cells infected with intracellular microorganisms (Yamamoto and 
Takeda, 2010). Almost all immune cells secrete cytokines.  
 
 
2.5.1. Cytokines  
Cytokines are 15 to 44 kD sized glycoproteins functioning as signal molecules 
between different immune cells. Thirty-five different cytokines have been 
described to date.  
Pro-inflammatory cytokines are generally produced by activated immune 
cells and enhance the inflammatory reactions, while anti-inflammatory 
cytokines inhibit the activated cells. Monocytes and macrophages produce 
initially pro-inflammatory cytokines: IL-1, TNF-α, INF-γ etc.  
We chose for investigation the pro-inflammatory (TNF-α and INF-γ) and 
anti-inflammatory cytokines (IL-10) as they have been earlier associated with 
persistent infection and granuloma formation (Monack et al., 2004; Sachinami 
et al., 2006). Moreover, the modulation of these cytokines is considered to be 
one of the principal mechanisms of protection against gastroenteric infections 
by probiotic lactobacilli though exact pathways and cells involved are not clear 
yet (Mileti et al., 2009). 
TNF-α is a pro-inflammatory cytokine that induces activation and recruit-
ment of neutrophils and produces intestinal epithelial barrier dysfunction, 
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contributing to the entry and colonization of pathogenic bacteria usually 
excluded from the subepithelial mucosa (Castillo et al., 2011). It is produced by 
several types of cells, but especially by macrophages. TNF-α is considered to be 
a major early mediator in the systemic inflammatory response syndrome 
observed during Gram-negative sepsis (Sakaguchi et al., 2006). Since TNF-α 
exerts its effects on almost every cell and organ within the body, the production 
of TNF-α is strictly regulated during infection (Castillo et al., 2011). 
INF-γ is produced predominantly by natural killer cells as a part of the innate 
immune response, and by CD4 Th1 and CD8 Tc lymphocyte. IL-12 and IL-18, 
secreted by activated macrophages, act both independently and synergistically 
on natural killer cells and helper T cells to induce the production of further INF-
γ, which activates the macrophages through a positive feedback loop. It 
contributes to the activation of macrophages to promote the effective killing of 
pathogens that can survive within them (Castillo et al., 2011). 
IL-10 is produced in a broad variety of cells, including Th2 cells, regulatory 
T cells, DCs, B cells, and macrophages (Mosser and Zhang, 2008). IL-10 is 
required to maintain the IgA (+) B cell population (Castillo et al., 2011). 
 
 
2.5.2. Gut as immune organ 
The gut immune system can be divided into three major compartments: 
organized gut-associated lymphoid tissue (GALT), the mucosal lamina propria, 
and the epithelium. 
The GALT consists of both isolated and aggregated lymphoid follicles and is 
one of the largest lymphoid organs, containing up to 80% of the cells within the 
immune system (Bezirtzoglou and Stavropoulou, 2011). Aggregated lymphoid 
follicles were named Peyer’s patches (PP) after their detailed description by the 
Swiss pathologist Johann Conrad Peyer in 1677. PPs are composed of 
aggregated lymphoid follicles surrounded by a particular epithelium, follicle-
associated epithelium (FAE) that forms the interface between the GALT and the 
luminal microenvironment. FAE contains specialized cells named M 
(microfold) cells. M cells are able to transport luminal material, like soluble 
proteins, antigens, viruses and bacteria, toward the underlying immune cells that 
activate or inhibit the immune response, leading to either tolerance or systemic 
immune cell response (Siebers and Finlay, 1996). M cells express an IgA-
specific receptor on their apical surfaces that mediate the transepithelial 
transport of sIgA from the intestinal lumen to underlying gut-associated 
organized lymphoid tissues (Mantis et al., 2002). 
The cellular composition of the FAE (i.e. the proportion of enterocytes and 
M cells) may be modulated by bacteria present in the gut lumen. Namely, 
pathogenic bacteria may increase the number of M-cells within the FAE 
(Savidge et al., 1991). 
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It has been shown earlier that in mouse PP exhibit about 60% of B-cells, 
25% of T-cells, 10% of dendritic cells and less than 5% of macrophages or 
polymorphonuclear neutrophil (Jung et al., 2010) 
Cell composition and cytokine production may affect the function of PP. 
Pro- and anti-inflammatory cytokines are known to modulate intestinal 
paracellular permeability. INF-γ, TNF-α, and IL-4 act on the membrane re-
ceptors of epithelial cells and increase tight junction permeability (Barreau et 
al., 2007). 
The activation of naïve T cells takes place in the GALT where differentiation 
of the activated lymphocytes occurs in PP, from where the lymphocytes 
circulate to the peripheral circulation. The gut immune system has a dual role: it 
provides defence against infectious agents, but also induces tolerance to 
harmless microbial antigens encountered in the gut. Oral tolerance is a major 
compartment of peripheral tolerance and its control of the immune response is 
not necessarily restricted locally but may include systemic effects (Vaarala, 
2003).  
Intestinal epithelial cells (IEC) are important in the presentation of oral 
antigens and in the regulation of intestinal immune responses. The changes in 
the epithelial structure of gut influence the intestinal immune system and vice 
versa. Permeability controls the amount and quality of antigenic exposure, e.g. 
dose and size of antigens encountered in the gut immune system. Activation of 
gut immune cells resulting in the secretion of cytokines may cause epithelial 
injury. Intestinal microbes have been suggested to be important regulators of the 
function and development of immune and epithelial cells.  
 
 
2.6. Lactobacilli  
Lactobacillus spp. belongs to a heterogeneous group of lactic acid bacteria 
(LAB). It includes about 20 genera within the phylum Firmicutes.  
LAB are divided into homolactic or heterolactic fermentation groups 
according to carbohydrate fermentation patterns (Kandler, 1986). In homolactic 
fermentation the end product of glycolyse is lactic acid. The majority of LAB 
are responsible for heterolactic fermentation. During pentose-phosphate 
pathway besides lactic acid, several organic acids, e.g. acetic, succinic, 
accompanied with ethanol and CO2, are produced.  
The bacteria from genus Lactobacillus are gram-positive, acid-tolerant, non-
spore forming rods. Lactobacilli sp. is the biggest group among LAB including 
135 species and 27 subspecies (Bernardeau et al., 2008). These numbers have 
been periodically re-evaluated due to the application of new genome-based 
molecular methods. The amount of lactobacilli has been estimated at almost 1% 
of colonic microbiota in humans (Louis et al., 2007), it varies due to several 
different factors, e.g. diet, environment and host individual properties 
(Stsepetova et al., 2011).  
6 
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Lactobacillus strains are present in the gastrointestinal tract of 70% of 
humans consuming a Western-like diet according to culture-based methods 
(Heilig et al., 2002). Ahmed and his colleagues have studied gut mucosal 
bacterial communities of 26 patients undergoing emergency resection of the 
large bowel with real-time PCR. They found that the terminal ileum had higher 
bacterial cell densities than the colon and that overall bacterial numbers were 
generally similar within the ascending, transverse, and descending colon 
(Ahmed et al., 2007). 
The dominant species differ between the mucosa-associated and fecal 
microbiota, and in an individual, the microbiota is relatively stable along the 
distal digestive tract (Mikelsaar et al., 1987; Lepage et al., 2005).  
Lactobacillus is a very heterogeneous genus, encompassing species with a 
large variety of phenotypic, biochemical, and physiological properties. Obli-
gately homofermentative (OHOL) lactobacilli, e.g. L. delbrueckii and L. aci-
dophilus, produce lactic acid as a major end product from glucose, and grow at 
45oC but not at 15oC. Facultatively heterofermentative lactobacilli (FHEL) 
L. casei and L. plantarum grow at 15oC and show variable growth at 45oC. They 
can produce acetate, if O2 is present. Obligatively heterofermentative lacto-
bacilli (OHEL), e.g. L. fermentum, L. brevis, produce lactic acid from glucose, 
along with CO2 and ethanol (Annuk et al., 2003; Hutt et al., 2006).  
Lactobacilli belong to the category of organisms classified as generally 
regarded as safe – GRAS for food and medical application (FAO/WHO, 2002).  
 
 
2.6.1. Probiotics 
Probiotics are defined as live microorganisms which, when administered in 
adequate amounts, beneficially affect the health of the host (FAO/WHO, 2002). 
The word “probiotic” is derived from the Greek words “pro” and “biotikos,” 
meaning “for life”.  
Several microbial genera have been used as probiotics, e.g. Bifidobacteria, 
Lactobacilli, Enterococci, and yeasts.  
Cell wall molecules of gram-positive LAB are composed of a thick pepti-
doglycan layer, proteins, teichoic acids, and polysaccharides. After interaction 
with host receptors and induction of signalling pathways, probiotic effects 
result. The main cell wall macromolecules have a similar basic architecture 
between species, but various modifications, such as glycosylation, can 
contribute to the strain-specific properties of probiotics (Lebeer et al., 2010). 
Specific health effects attributed to probiotics that have been investigated 
include alleviation of diarrheal illness, constipation, urogenital infections, atopic 
diseases, and neonatal necrotizing enterocolitis (Kontiokari et al., 2003; Reid 
and Bruce, 2006, Gerritsen et al., 2011). Though probiotics are generally safe, 
they should be used with caution in patients who have lowered immunity or 
integrity of the intestinal mucosa. There are three theoretical concerns regarding 
the safety of probiotics: 1) the occurrence of disease, such as bacteremia or 
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endocarditis; 2) toxic or metabolic effects on the gastrointestinal tract; and 
3) the transfer of antibiotic resistance in the gastrointestinal microbiota 
(Snydman, 2008).  
 
 
2.6.2. Mechanisms of action of probiotic lactobacilli 
The exact mode of how probiotics act is scarcely known. Lactobacilli can 
influence the host by using different mechanisms depending on strain and 
species-specific properties. Their efficacy has been studied concerning defence 
against infectious and non-infectious lesions. 
First, in the case of infective agents, probiotic microorganisms may exert 
their action through a modulation of the intestinal microbiota, which may result 
from competitive metabolic interactions with potential pathogens. Lactic and 
non-lactic acids, and hydrogen peroxide enable to inhibit or kill pathogens 
(Annuk et al., 2003; Hütt et al., 2006). Furthermore, lactobacilli produce 
bacteriocins at the end of the exponential growth-phase (Montalban-Lopez et 
al., 2012). They are ribosomally synthesized proteins with variable molecular 
weight, genetic origin, biochemical properties, and mode of action. The 
bactericidial influence is selective for prokaryotes and varies depending on the 
producing species. Producer strains are immune to their own bacteriocins 
because they possess genes that encode immunity mechanisms, which enable a 
distinction between “self” and “non-self” (Pessione, 2012). 
Second, in the gut lactobacilli seemingly compete with the pathogen for the 
adhesion sites, nutrients and antagonistic relations (Hutt et al., 2006; Stsepetova 
et al., 2011). Recently, McNulty and his colleagues demonstrated that probiotic 
strains are able to change the metabolic pathways of the carbohydrates of 
indigenous microbiota (McNulty et al., 2011). 
Third, probiotics have been proposed to modulate host defenses by 
influencing the intestinal immune system by increasing phagocytosis, 
modifying cytokine production, or enhancing IgA production (Alakomi et al., 
2000; Castillo et al., 2011). Immune stimulation has been suggested to underlie 
the anti-infection and anti-carcinogenic effects of lactic acid bacteria (Gill et al., 
2000). At intracellular level it has been shown that probiotic strains can inhibit 
NF-kappa B activation (Petrof et al., 2004).  
Fourth, positive affection to the intestinal barrier function by fortifying the 
epithelial tight junctions has also been postulated (Doron et al., 2005). 
By using these abovementioned mechanisms, probiotics can not only 
potentially modulate the intestinal microbiota composition, but also prevent 
pathogenic bacterial overgrowth. 
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3. AIMS OF THE STUDY 
We tested the hypothesis of whether probiotic Lactobacillus sp. as adjunct to 
antimicrobial treatment could help to resolve persistent S. Typhimurium 
infection in mice and studied the possible mechanisms behind it. 
The goal of the present study was to detect the effect of lactobacilli of 
human origin (the probiotic strain Lactobacillus fermentum ME-3 DSM 14241 
and Lactobacillus acidophilus E1) on microbiological, histological, bio-
chemical, and immunological status of mice in Salmonella Typhimurium 
persistent infection model, and to detect the impact of the probiotic strain 
Lactobacillus plantarum Inducia DSM 21379 on total count of lactobacilli and 
immunological response in the gut of mice. 
The following objectives were set: 
 
1.  To detect viable S. Typhimurium in the blood, liver, spleen, and gut; total 
count of lactobacilli in gut; granulomas in the liver and spleen; oxidative 
stress related indices (LPO, GSSG/GSH), and cytokines (TNF-α, INF-γ and 
IL-10) in the liver and gut of mice infected with S. Typhimurium. 
 
2.  To test the influence of two selected Lactobacillus spp strains of human 
origin, probiotic strain L. fermentum ME-3 and L. acidophilus E-1, on the 
Salmonella enterica serovar Typhimurium infection in mice by detecting 
salmonella, the total count of lactobacilli, morphologic changes in the liver 
and spleen, and oxidative stress related indices. 
 
3.  To determine the impact of Lactobacillus plantarum Inducia on the total 
count of intestinal lactobacilli and the response of gut-associated lymphoid 
tissue of the ileum and colon of healthy mice after 30 days of intake of 
cheese containing L. plantarum Inducia. 
 
4.  To detect if the L. fermentum ME-3 in combination with ofloxacin would 
influence the viability of S. Typhimurium in the blood, liver and spleen, the 
development of liver and spleen granulomas and the indices of oxidative 
stress in the mucosa of the ileum.  
 
5.  To assess the profile of pro- and anti-inflammatory cytokines in the gut and 
liver evoked by the addition of L. fermentum ME-3 to ofloxacin treatment in 
the persistent infection model of S. Typhimurium. 
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4. MATERIAL AND METHODS 
4.1. Study design 
For the experimental infection in studies I–III we applied a murine model of S. 
Typhimurium infection (Santos et al., 2001; Tsolis et al., 2011). A total of 193 
(47, 72, 54 and 20 in studies I–IV, respectively) NIH line conventional male 
mice (Kuopio, Finland), who were 6 weeks old at the beginning of the 
experiments, were used. The mice were divided into separately housed groups 
depending on the following treatments. All animal experiments were approved 
by the Committee of Animal Experiments of Estonian Ministry of Agriculture 
(06 03505, 07 04679, 06 08560). 
A commercial diet R-70 (Lactamin, Sweden) and tap water ad libitum were 
available throughout studies I–III. Daily feeding was similar in study IV, while 
at night 10 mice were administered cheese (4,4g per mouse) containing 
L. plantarum Inducia 2×108 cfu/g and another 10 mice from control group 
received cheese without L. plantarum Inducia. The faecal material was collected 
before the experiment and then on the 10-th and 15-th day of the experiment per 
cage. After 30 days the 20 mice were sacrificed by cervical dislocation.  
Experimental infection studies (I–III) included control groups treated with 
0.5 ml of sterile PBS orally by intragastric gavage (7, 11, and 6 mice, 
respectively) and groups challenged with a clinical isolate of Salmonella 
Typhimurium (16, 22 and 12 mice, respectively) (Table 1, Fig. 1–3). 
The deaths of mice were registered and all surviving animals were sacrificed 
using cervical dislocation either on the 5th (study III) or on the 10th day (studies 
I–III) following S. Typhimurium administration. The autopsy was performed 
under sterile conditions using a Class II microbiological safety cabinet (Jouan, 
France). Bacteriological tests from heart blood (10 µl), liver, spleen and gut 
were were carried out immediately, while samples for biochemical testing were 
maintained at –800C for up to three months before testing. The samples for 
histological investigation were collected from the liver, spleen and ileum, 
placed into 10% formaldehyde for fixation and processed further for paraffin 
embedding prior to hematoxylin and eosin staining. 
In study I, the impact of the administration of L. acidophilus E-1 and pro-
biotic L. fermentum ME-3 on experimental S. Typhimurium infection was eva-
luated in Gr 3 (n=14). Namely, for 5 consecutive days before and 10 days after 
challenging the mice with S. Typhimurium, the aforementioned lactobacilli 
were added to ultra-pasteurized milk. The mice of Gr 4 (n=10) were fed with 
ultra-pasteurized milk fermented with L. acidophilus E-1 and L. fermentum  
ME-3 for 15 consecutive days and served as a positive control group. 
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Table 1. Study groups and study designs presented in papers I–IV 
No. of experimental animals Study description Presented in paper 
 
47 NIH male mice 
 
Gr 1 PBS (n=7) 
Gr 2 S. Typhimurium (n=16)  
Gr 3 L. acidophilus E-1 and L. 
fermentum ME-3 for 5 days prior 
challenge with S. Typhimurium 10 
days after (n=14) 
Gr 4 L. acidophilus and L. fermentum 
ME-3 for 15 days (n=10) 
 
Intervention study 
Elaboration of the persistent S. 
Typhimurium mouse model. 
Evaluation of the impact of L. 
fermentum ME-3 and L. 
acidophilus E-1 on 
microbiological, morphological and 
OxS-indicative markers of gut 
mucosa (Figure 1). 
 
I 
 
72 NIH male mice 
 
Gr 1 S. Typhimurium (n=22) 
Gr 2 S. Typhimurium and ofloxacin; 
(n=13) 
Gr 3 S. Typhimurium and L. 
fermentum ME-3 (n=13) 
Gr 4 S.Typhimurium and ofloxacin 
and L. fermentum ME-3 (n=13) 
Gr 5 PBS (n=11) 
 
Intervention study 
Detection of microbiological, 
antioxidative and morphological 
response in combined treatment of 
ofloxacin and L. fermentum ME-3 
in S. Typhimurium murine model 
(Figure 2). 
 
II 
 
54 NIH male mice  
 
Gr 1 S. Typhimurium (n=12) 
Gr 2 S.Typhimurium and ofloxacin 
(n=12) 
Gr 3 S.Typhimurium, ofloxacin and 
L. fermentum ME-3 (n=12) 
Gr 4 L. fermentum ME-3 (n=12) 
Gr 5 PBS (n=6) 
Intervention study 
Detection of microbiological, 
immunological, antioxidative and 
morphological response in 
combined treatment of ofloxacin 
and L. fermentum ME-3 in S. 
Typhimurium murine model 
(Figure 3). 
 
III 
20 NIH male mice  
 
Gr 1 Control cheese without L. 
plantarum Inducia (n=10) 
Gr 2 Cheese containing L. plantarum 
Inducia (n=10) 
Intervention study  
To determine the impact of 
administration of Lactobacillus 
plantarum Inducia on the gut-
associated lymphoid tissue and 
total count of lactobacilli in gut of 
mice (Figure 4). 
IV 
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In study II and III we aimed to detect the impact of combined treatment of 
ofloxacin and L. fermentum ME-3 in S. Typhimurium murine model. Therefore, 
L. fermentum in drinking water was added to ofloxacin (OFL) treatment of the 
experimental S. Typhimurium infection. OFL (Hoechst, Germany) at doses of 
20 mg/kg (Fu et al., 1990) was diluted in 0.5 ml of PBS and given 
intragastrically by a sterile syringe with a blunt-ended tube once daily. 48 hours 
after the challenge with S. Typhimurium, mice were treated either with OFL Gr 
2 of study II and III (13 and 12 mice, respectively) or with the combination of 
OFL and L. fermentum ME-3 (13 in Gr 4 of study II and 12 mice in Gr 3 of 
study III). Gr 3 mice (n=13) in study II received L. fermentum ME-3 48 hours 
after challenge with S. Typhimurium for 8 days, while Gr 4 mice (n=12) in 
study III were administered L. fermentum ME-3. 
 
 
Day 0 -9
Gr 1 
(n=7)
PBS 
Day -5 
Gr 3 (n=14) 
L. acidophilus E-1
L. fermentum ME-3 
S. Typhimurium
Gr 4 (n=10)
L. acidophilus E-1
L. fermentum ME-3
Day 10 
Day 15 
Gr 2 (n=16)
S. Typhimurium
Autopsy
Autopsy
L. acidophilus E-1
L. fermentum ME-3 
47 NIH mice
 
 
Figure 1. Design of study I. 
47 NIH male mice were divided into four groups. Gr 1 (n=7) mice were PBS treated for 
10 days. Gr 2 (n=16) mice were infected with S. Typhimurium on Day 0. Gr 3 (n=14) 
mice were pre-treated with L. fermentum ME-3 and L. acidophilus E-1 for 5 days before 
the challenge with S. Typhimurium. The administration of lactobacilli was continued up 
to Day 10. Gr 4 (n=10) received aforementioned lactobacilli for 15 days.  
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Day 0 
Day 2-9 
Day 10
S. Typhimurium (n=61)  
Gr 5
(n=11)
PBS 
72 NIH mice
Ofloxacin
L. fermentum ME-3 L. fermentum ME-3
Ofloxacin
Autopsy
Gr 1 (n=22)
Gr 2  (n=13)              Gr 3 (n=13)                       Gr 4 (n=13)                       
 
 
Figure 2. Design of study II. 
72 NIH male mice were divided into 5 groups. Gr 1 (n=22) mice were challenged with 
S. Typhimurium on Day 0. Gr 2 (n=13) mice were infected with S. Typhimurium on 
Day 0 and, 48 hours after that, treated with ofloxacin daily for 8 days. Gr 3 (n=13) mice 
were infected with S. Typhimurium on Day 0 and 48 hours after that were treated with 
L. fermentum ME-3 continuously in drinking water for 8 days. Gr 4 (n=13) mice were 
infected with S. Typhimurium on Day 0 and 48 hours after that treated with ofloxacin 
daily and L. fermentum ME-3 continuously in drinking water for 8 days. Gr 5 mice 
(n=11) received PBS via intragastric gavage once daily for 10 days.  
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Day 0 
Day 2-4
Day 5
Day 10
54 NIH mice
S. Typhimurium (n=36) 
Gr 5 
(n=6)
PBS 
Autopsy
Ofloxacin
Ofloxacin
L. fermentum ME-3
Gr 4 (n=12)
L. fermentum
ME-3 
Ofloxacin
(n=6)
Ofloxacin
L. fermentum ME-3
(n=6)
Autopsy
Gr1 (n=12)
Day 6-9
Gr 2 (n=12)                          Gr 3 (n=12)
Autopsy
(n=6) (n=6)                                  (n=6)
Autopsy
(n=6)
 
 
Figure 3. Design of study III. 
54 NIH male mice were divided into 5 groups. Autopsy was performed at two time 
points in Gr 1-Gr 4 mice. Half of the mice (n=6) were sacrificed on Day 5 and the other 
half (n=6) on Day 10. Gr 1 (n=12) mice were challenged with S. Typhimurium on Day 
0. Gr 2 (n=12) mice were infected with S. Typhimurium on Day 0 and, 48 hours after 
that, treated with ofloxacin (OFL) daily. Gr 3 (n=12) mice were infected with S. 
Typhimurium on Day 0 and 48 hours after that treated with L. fermentum ME-3 
continuously in drinking water OFL daily. Gr 4 (n=12) mice were administered L. 
fermentum ME-3 continuously in drinking water for 8 days. Gr 5 mice (n=6) received 
PBS via intragasric gavage once daily for 10 days.  
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20 NIH mice
Day 0 -29
Day 30 
Gr 1 (n=10)
Control cheese without
L. plantarum INDUCIA 
Gr 2 (n=10)
Cheese with
L. plantarum INDUCIA
Autopsy
 
Figure 4. Design of study IV. 
20 NIH mice were divided into 2 groups. Gr 1 (n=10) mice were administered cheese 
containing L. plantarum Inducia and Gr 2 (n=10) received control cheese without 
L. plantarum Inducia for 29 days. 
 
 
4.2. Microbial strains  
4.2.1. Salmonella Typhimurium 
The clinical isolate of Salmonella enterica serovar Typhimurium was kindly 
provided by the Estonian Health Board Laboratory of Microbiology. After 
cultivation on blood agar for 24 h at 37ºC, the colonies were suspended in PBS, 
and adjusted to the concentration of 5×104 CFU/ml. The mice were inoculated 
intragastrically with a single 0.5 ml dose of the S. Typhimurium suspension 
(5×104 CFU/ml) using a sterile syringe with a blunt-ended tube. As we aimed to 
study a persistent infection we applied the adjusted minimal dose of 
S. Typhimurium from preliminary experiments. 
 
 
4.2.2. Lactobacilli 
All three Lactobacillus strains used in our studies were isolated from the faecal 
samples of Estonian children during a comparative study of the gut microbiota 
of Estonian and Swedish children (Mikelsaar et al., 2002). 
These strains were identified as L. fermentum, L. acidophilus and L. plan-
tarum by API 50 CHL (bioMérieux, France) and internal transcribed spacer 
polymerase chain reaction (Annuk et al., 2003). Two strains are patented and 
deposited in DSM: L. plantarum Inducia DSM 21379 and L. fermentum ME-3 
DSM 14241.  
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L. fermentum ME-3 demonstrated a high antagonistic activity against S. 
Typhimurium (inhibition zone of 13–15 mm) and a total antioxidative activity 
(TAA) value (29±0.7%) in vitro, while the L. acidophilus E-1 had minimal 
antagonistic activity against S. Typhimurium (inhibition zone of 0–2 mm) and a 
low-grade antioxidativity (TAA value as 8±3%) (Kullisaar et al., 2002). 
In our study I, L. fermentum ME-3 and L. acidophilus E-1 strains were 
cultivated separately in de Man-Rogosa-Sharpe (MRS) broth (Oxoid, UK) at 
37ºC for 24 h in a 10% CO2 environment. The strains of both lactobacilli in 
equal volumes (5×107 CFU/ml) were added to ultra-pasteurized milk and 
fermentation was carried out at 37ºC for 48 h in a 10% CO2 environment. The 
product was divided into daily portions for the whole experiment and 
maintained at –20ºC until administration to mice. There was no antagonism 
between these two strains of lactobacilli in vitro. 
In studies II and III, the lyophilized L. fermentum ME-3 (Probiotical s.r.l, 
Novara, Italy) was suspended in PBS to a final concentration of 5×107CFU/ml. 
During the experiments each mouse consumed approximately 5 ml of L. 
fermentum ME-3 containing PBS, and received 2.5×108 CFU of lactobacilli 
daily. 
In study IV, we applied probiotic L. plantarum Inducia DSM 21379 in 
concentration of 2×108CFU/g of cheese. Total antioxidative activity (TAA) and 
total antioxidative status (TAS) of Lactobacillus plantarum Inducia DSM 21379 
demonstrated high values (26±1.2% and 0.13±0.04, respectively). 
 
 
4.3. Antibacterial susceptibility testing 
In study II, the value of minimal inhibitory concentration (MIC) of ofloxacin to 
S. Typhimurium on Mueller-Hinton media (Oxoid, UK) was measured by the E-
test (Oxoid, UK). 
The combinative effect of OFL and L. fermentum ME-3 against 
S. Typhimurium was evaluated by two following in vitro tests. First, in the 
overlay test, 10 ml of the MRS agar (Oxoid, UK) containing 108 CFU/ml of 
L. fermentum ME-3 was poured onto plates and incubated in 10% CO2 at 37°C 
for 48 h. E- test was applied after overlay with 5 ml 1.0% (w/w) Isosensitest 
agar (Oxoid, UK), inoculation with S. Typhimurium in concentration of 
108CFU/ml, and incubation in microaerobic conditions at 37°C for 24 h. 
Second, in the dilution test two-fold serial dilutions of OFL in broth were 
prepared. S. Typhimurium and L. fermentum ME-3 solutions were adjusted 
according to the 0.5 McFarland turbidity standard and 10 μl of the suspension 
was placed into the broth (Nutrient broth No2 Oxoid, UK) containing OFL and 
the minimal bactericidial values were detected by plating. All susceptibility 
tests were performed in duplicate.  
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4.4. Bacteriology  
At autopsy 10 μl of the heart blood was cultured in thioglycolate broth (Oxoid, 
UK) and after 24 hours onto Bismuth Sulphite agar and 5% blood agar (study I), 
McConkey agar (study II) and XLD (study III) (Oxoid, UK) for detection of S. 
Typhimurium and on the de Man-Rogosa-Sharpe (MRS) (Oxoid, UK) for 
lactobacilli. The samples of liver, spleen and intestine were weighed, 
homogenized with sterile glass powder, serially diluted (10–2–10–7) in PBS (pH 
7.2), and 0.1 ml of each 10-fold dilution was seeded on the aforementioned 
media. The incubation was performed both at 37ºC for 24 h in an aerobic 
environment (Salmonella) or in a 10% CO2 environment 48 hours (Lacto-
bacillus). The particular characteristic colonies were counted, identified at the 
genus level and the counts of bacteria were assessed. The detection level of the 
bacteria was 2 log CFU/ml for blood, 2 log for liver and 1.7 log CFU/g for 
intestinal samples (study I), while in study II ≥3.0 log CFU/g, respectively. The 
total counts of lactobacilli were calculated as CFU/mg.  
 
 
4.5. Morphological investigation  
Morphological investigation was performed by Professor R.H. Mikelsaar and 
Dr. H. Tamme at the Department of Pathological Anatomy and Forensic 
Medicine, University of Tartu. Samples from the ileum, colon, liver and spleen 
were fixed in 10% formaldehyde and processed further for paraffin embedding. 
Tissue sections (approx. 5 m) were stained with haematoxylin and eosin. 
Destructive and inflammatory signs, namely hyperaemia, necrosis, number of 
typhoid nodules and hyperplasia of Peyer’s patches, were evaluated. The two 
pathologists evaluated coded slides in a blinded manner. The inflammatory 
changes were graded between 0 and 5, with 0 for no changes and 5 for severe 
changes in study I–II. The degree of necrosis was scored on a scale ranging 
from 1 to 3 (1 – weak, 2 – moderate, and 3 – strong) (study III). The hyperplasia 
of lymph follicles was evaluated similarly in study IV.  
 
 
4.6. Biochemical assays  
All biochemical studies were performed in collaboration with senior researchers 
T. Kullisaar, K. Zilmer, A. Rehemaa and R. Mahlapuu from the Department of 
Biochemistry, University of Tartu. The mucosa of ileum (study I–II), liver and 
mucosa of small intestine (study III) were obtained during autopsy and stored at 
–80C for a maximum of three months. All biochemical indices were measured 
simultaneously after homogenisation in a 1.15% KCl solution (1:10).  
 
 
33 
4.6.1. Total antioxidative activity  
Total antioxidative activity (TAA) was assessed using the linolenic acid test 
described by Kullisaar (Kullisaar et al., 2002). It was expressed as the inhibition 
of the peroxidation of the linolenic acid (LA) standard by the sample, measured 
as a percentage. The high numerical value of TAA (>10%) indicates the high 
total antioxidative activity of the sample.  
 
 
4.6.2. The indices of oxidative stress  
4.6.2.1. Lipid peroxidation  
Malondialdehyde (MDA) was used as an indicator of lipid peroxidation (LPO), 
and was measured using a commercial kit, Bioxytech LPO-586 (Oxis Inter-
national, Catalog No. 21012). The assay is based on the reaction of a chro-
mogenic reagent, N-methyl-2-Phenylindole, with malonedialdehyde (MDA) and 
hydroxynonenals at 45º C, yielding a stable chromophore with maximal 
absorbance at 586 nm. The results were calculated according to the kit formula 
and the tissue values were given in pmol/mg protein. 
 
4.6.2.2. Glutathione redox status  
Glutathione redox ratio was tested by measuring total glutathione and oxidized 
glutathione using the method described by Griffith (Griffith, 1980). The 
glutathione content was quantified by comparison with a standard curve 
generated using specific amounts of glutathione. The amount of reduced 
glutathione (GSH) and oxidised glutathione (GSSG) was expressed as µg/ml, 
and demonstrated as (GSSG/GSH).  
 
 
4.6.3. Iron detection  
A special kit for iron detection (Sigma 565, Sigma Diagnostics, USA) was used 
for assessment of iron levels and iron-binding capacities (Kaur et al., 2001). All 
procedures were performed in triplicate. Iron concentration was calculated using 
the formula of the applied kit. Iron content was expressed as mol/l. The 
percentage of saturation of iron-binding capacity (indicates the percent of bound 
iron) was calculated from data measured with the kit. 
 
 
4.7. Immunological assays 
The immunological studies were performed in collaboration with senior 
researcher T. Kullisaar from the Department of Biochemistry, University of 
Tartu. 
9
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4.7.1. Detection of INF-γ, IL-10, TNF-α  
The mucosa of the small intestine and liver obtained at autopsy was processed 
to the cytokine Mouse Immunoassay (R&D Systems, USA). This assay 
employs the quantitative sandwitch enzyme immunoassay technique. We 
followed the recommendations from the manufacturer. The purified polyclonal 
antibodies specific for mouse INF-γ, IL-10, TNF-α were pre-coated onto a 
microplate. Standards, control, and samples were pipetted into the wells and any 
aforementioned mouse cytokines present were bound by the immobilized 
antibody. After washing away unbound substances, an enzyme-linked poly-
clonal antibody specific for mouse corresponding cytokines was added to the 
wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells. The enzyme reaction yielded a blue 
product that turned yellow when the Stop Solution was added. The intensity of 
the measured color was in proportion to the amount of mouse cytokines bound 
in the initial step. The sample values were then read off the standard curve.  
 
 
4.8. Statistical analysis 
Statistical analyses were performed using the SigmaStat (Jandel Scientific), and 
R 2.6.2 (a Language and Environment; http://www.r-project.org) software. 
The Fisher exact test was applied in comparing categorical values, and the 
Mann-Whitney rank sum test for continuous variables. The tests were selected 
according to data distribution: the Student t-test for describing the continuous 
indices, the Mann-Whitney test was used for comparing unevenly distributed 
data. The p-values less than 0.05 were considered statistically significant. In the 
case of group comparisons Bonferroni correction was applied. (4 groups  
p-value 0.012). The OR values were calculated to describe the impact of the 
intake of L. plantarum containing cheese on the lymph follicles of the ileum and 
colon of mice in study IV.  
Due to similarities in study design we summarized the results of micro-
biology, morphology and biochemistry of study II and study III. 
The One-Way ANOVA with Bonferroni correction test was used in group 
comparisons if we compared six unmatched groups by analysing the results of 
LPO values. The Kruskal-Wallis One-Way Analysis of Variance on Ranks was 
used in analyzing the results of glutathione redox ratio. The group of mice 
infected with S. Typhimurium and treated with the combination of ofloxacin 
and lactobacilli was set as a reference in all comparisons.  
A linear logistic regression model was applied to find the relationship 
between the presence of typhoid nodules in the liver and the values of cytokines 
in the small intestine and liver. 
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5. RESULTS AND DISCUSSION 
5.1. Antibacterial susceptibility testing  
The minimal inhibitory concentration (MIC) values of ofloxacin to S. Typhi-
murium were 0.19 µg/ml and 8 µg/ml to L. fermentum ME-3. After coculti-
vation of S. Typhimurium and L. fermentum ME-3 a six-fold decrease in the 
MIC values (0.032 µg/ml) of ofloxacin was observed. We considered S. 
Typhimurium susceptible to ofloxacin according to NCCLS quidelines as the 
MIC breakpoint value to ofloxacin is ≤2 µg/ml (Wayne, 2006).  
 
 
5.2. The survival of mice 
The survival of mice challenged with S. Typhimurium was high. Altogether 
four mice died (4/50; 8%).  
Namely, 2/16 mice in S.Typhimurium challenged Gr 2 in study I died on 
Day 8 and 9 respectively and 2/22 in S. Typhimurium challenged Gr 1 from 
study II on Day 8. We excluded the data of deceased mice from further analysis. 
One mouse died in Gr 3 challenged with S. Typhimurium and pre-and post-
treated with L. fermentum ME-3 and L. acidophilus in study I. 
All mice from studies III and IV survived the experiment.  
 
 
5.3. Microbiological data  
5.3.1. Detection of S. Typhimurium 
In study I, the number of mice with viable S. Typhimurium in the blood, liver 
and gut was similar in Gr 2 of mice infected with S. Typhimurium and in Gr 3 
pre-treated with L. fermentum and L. acidophilus before challenge with 
S. Typhimurium. 
The presence of S. Typhimurium was highest in the liver 12/14 in Gr 2 and 
8/13 in Gr 3, in gut 7/14 and 6/13, and in heart blood 3/14 and 3/13, res-
pectively. 
Figure 5 depicts the results of study II and III. The number of mice with 
viable S. Typhimurium in the gut decreased in both ofloxacin containing treat-
ment regimens. Namely, ofloxacin treatment (p<0.006) and its combination 
with L. fermentum ME-3 (p<0.001). However, the decrease in the number of 
mice with viable S. Typhimurium in the liver was observed only if L. fermentum 
was added to ofloxacin treatment (p<0.001) (Fig. 5).  
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Figure 5. Proportion (%) of survived mice with viable Salmonella Typhimurium in the 
blood, liver and gut of mice groups challenged with S. Typhimurium (Summarized 
results of mice sacrificed on Day 10 from studies II and III). Gr 1 (n=26) indicates mice 
challenged with S. Typhimurium. Gr 2 (n= 19) stands for mice challenged with S. 
Typhimurium mice and treated with ofloxacin. Gr 4 from study II +Gr 3 from study III 
(n=19) received ofloxacin and L. fermentum ME-3 after challenge with S. Typhi-
murium. Gr 3 mice (n=13) from study II were administered L. fermentum ME-3 after 
S. Typhimurium (Fisher exact test).  
 
 
5.3.2. Total count of lactobacilli in gut of mice 
After application of three strains of lactobacilli of human origin from different 
fermentation groups: L. fermentum ME-3 belongs to OHEL group, L. aci-
dophilus E-1 to OHOL, and L.plantarum Inducia to FHEL group, we found the 
unexpected results in the total count of lactobacilli (range and median in  
log cfu/g) 
In study I, the intake of L. fermentum ME-3 and L. acidophilus E-1 for 15 
days reduced the total count of lactobacilli in ileum if compared to the control 
group that received PBS (8.3–9.6/8.8 vs. 8.7–10.5/9.6, p<0.05 respectively). In 
studies II and III, no statistically significant alterations in the total number of 
lactobacilli were detected. In contrast to that, the increase of total count of 
lactobacilli was detected in the ileum and colon of mice after longer admi-
nistration (30 days) of L. plantarum containing cheese in study IV (Table 2). 
Still, the higher counts of intestinal lactobacilli were associated with absence 
of granulomas in the liver of S. Typhimurium experimental infection in study II. 
Namely, we found a statistically significant difference (p=0.002) when we 
compared the total intestinal lactobacilli counts from the mice with and without 
granulomas in the liver. Moreover, in study III the total number of lactobacilli 
in the small intestine of groups administered L. fermentum ME-3 (Gr 3 and Gr 
4) was negatively correlated with the values of INF-γ (r=–0.422; p=0.039) and 
positively correlated with IL-10 (r=0.551; p=0.005).  
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Table 2. Total count of lactobacilli (log cfu/g) in faeces (days 0, 10 and 15) and in the 
ileum and colon (obtained at autopsy on Day 30) (range/median log cfu/g) of mice fed 
with cheese containing L. plantarum Inducia DSM 21379. 
Faecal samples 
Days 0–15 
Intestinal samples 
Day 30 
Control group (cheese  
without L. plantarum Inducia 
DSM 21379 was administered) 
(n=10) 
Test group (cheese  
containing L. plantarum 
Inducia DSM 21379 was 
administered) (n=10) 
Day 0  6.7 7.6 
Day 10 8.0 8.3 
Day 15 7.0 8.0 
Day 30 ileum 3.0–7.1/5.95* 6.3–7.7/6.95* 
Day 30 colon 4.4–7.3/6.65** 6.9–7,8/7.45** 
Student t-test *p= 0.001; **p<0.05 
 
 
The differences in the total counts of lactobacilli in different experiments are 
probably due to Lactobacillus sp. strain specificity and the duration of intake of 
the strains. Namely, L. plantarum Inducia was administered for a longer period 
than in studies with S. Typhimurium infection (30 days vs 15 and 10 days).  
Another important issue is the different carrier substances used for 
lactobacilli during separate studies: ultra-pastorized milk (study I), water (study 
II and III), and cheese (study IV). Hence, different microbial communities were 
involved, e.g. beside several starter strains the carrier cheese contains some 
nonstarter LAB strains that have survived pasteurization. Moreover, dietary 
calcium, present in milk, has been recognised to decrease colonisation and 
translocation of intestinal Gram-negative pathogens both in rats (Bovee-
Oudenhoven et al., 1999) and in humans (Bovee-Oudenhoven et al., 2003). The 
dietary intake of calcium and phosphate results in the formation of a calcium 
phosphate complex in the proximal part of small intestine that adsorbs and 
precipitates luminal cytotoxic components, e.g. bile acids and fatty acids and 
reduces epithelial cell damage. This subsequently stimulates growth of endo-
genous lactobacilli (Bovee-Oudenhoven et al., 1999), which exert antagonistic 
activity towards foodborne pathogens (Trautvetter et al., 2011). 
 
 
5.4. Morphological data 
In study I, the number of mice with granulomas in the liver was similar in mice 
infected with S. Typhimurium of Gr 2 and in the ones of Gr 3 pretreated with L. 
fermentum and L. acidophilus (11/14 and 10/13, respectively).  
Figure 6 depicts summarized results of mice sacrificed on Day 10 from 
studies II and III. The addition of L. fermentum ME-3 to ofloxacin decreased the 
number of mice with granulomas both in the liver (p<0.001), and in the spleen 
10 
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(p<0.001) if compared to the ones infected with S. Typhimurium. In the spleen, 
the ofloxacin treatment after S. Typhimurium challenge decreased the number 
of mice with granulomas compared to mice infected with S. Typhimurium 
(p<0.001) (Fig. 6).  
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Figure 6. Proportion of survived mice with granuloma in the liver and/or spleen of mice 
groups challenged with S. Typhimurium (Summarized results of mice sacrificed on Day 
10 from studies II and III). Gr 1 (n=26) indicates S. Typhimurium challenged mice. Gr 2 
(n= 19) stands for mice challenged with S. Typhimurium and treated with ofloxacin. Gr 
4 from study II +Gr 3 from study III (n=19) received ofloxacin and L. fermentum ME-3 
after challenge with S. Typhimurium. Gr 3 mice (n=13) from study II were administered 
L. fermentum ME-3 after S. Typhimurium (Fisher exact test). 
 
 
Figure 7. Histological sample (H&E,x400) of the liver granuloma from a mouse 
challenged with S. Typhimurium (Gr 2, study I).  
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Our results concerning the formation of granulomas in the liver and spleen are 
in accordance with an earlier study (Thygesen et al., 2000). Salmonella 
Typhimurium was rapidly taken up by the reticuloendothelial system and 
induced reversible changes in the spleen of rats. The formation of granuloma 
and infiltration with macrophages was detected on Day 3 after the challenge 
with S. Typhiumurium (Thygesen et al., 2000).  
Next we evaluated the hyperplasia of lymphoid follicles in gut. According to 
scoring results, we found that all tested bacteria, L. fermentum ME-3, L. 
acidophilus E-1 and S. Typhimurium influenced the number of lymph follicles 
of gut in study I. The hyperplasia of lymph follicles increased in Gr 2 mice 
challenged with S. Typhimurium and Gr 4 mice administered L. fermentum  
ME-3 and L. acidophilus E-1 as compared to the mice of Gr 1 that received 
PBS (p<0.01; p<0.05, respectively). 
Similarly, the intake of cheese containig Lactobacillus plantarum Inducia 
DSM 21379 during a month enhanced the count of lymphatic follicles in the 
ileum 3.5 times and in colon 6 times in comparison with control mice in study 
IV (Table 3). These results refer to the trend of enhancement of the defence 
capability of gut-associated lymphoid tissue by administration of probiotic 
lactobacilli.  
 
Table 3. Number of mice with increased count of lymph follicles (scores 2 and 3) after 
administration of cheese containing Lactobacillus plantarum Inducia DSM 21379 for 
30 days.  
Mice group  Ileum Colon 
Animals consumed cheese containing  
L. plantarum Inducia DSM 21379  
6/10 8/10 
Control cheese consumed animals  3/10 4/10 
In ileum OR 3,5 (95%CI 0.5–22.3) 
In colon OR 6.0 (95%CI 0.8–44) 
 
 
5.5. Biochemical indices  
5.5.1. Study I 
In study I, we evaluated the impact of S. Typhimurium on OxS indices, i.e. the 
lipid peroxidation, the ratio of oxidised and reduced glutathione, and saturation 
of Fe. The OxS indices increased significantly in mice challenged with S. 
Typhimurium as compared to the control animals receiving PBS (p<0.01; 
p<0.05, respectively) (Table 4).  
Treatment of the mice with L. fermentum ME-3 and L. acidophilus E-1 
before and during experimental infection had a positive influence on excessive 
OxS indicative parameters, except glutathione redox ratio. The reduction of 
40 
LPO, iron content, iron binding protein saturation, and the increase of the values 
of the gut mucosal TAA as compared to the same indices of S. Typhimurim 
challenged mice was found (p<0.05). 
The mice not challenged with S. Typhimurium and administered L. 
acidophilus and L. fermentum ME-3 showed moderate changes in oxidative 
stress indices as compared to the PBS group: the elevated LPO (p<0.01). 
 
Table 4. The mean values with standard deviations of LPO, TAA, GSSG/GSH, Fe, and 
saturation with Fe content in ileum mucosa in study I. 
Mice groups 
LPO 
(pmol/mg 
protein) 
in gut 
TAA (%) GSSG/GSH Fe (μmol/L) 
Saturation 
with Fe (%) 
PBS 1096.71/2/3 380.51/2 0.120.021/2 1065 1565 
S. Typhimurium 297581/4/5 41125 0.440.3751 23125/6 29145/6 
L. fermentum ME-3+L. 
acidophilus E-1+ S. 
Typhimurium 
224462/5 5151/ 3/5 0.340.152/3 15106 20106 
L. fermentum ME-3+L. 
acidophilus E-1 157413/4 3022/3 0.10.033 115 188 
Common numbers in superscription indicate statistically significant differences (1, 2, 3, 4 p<0.01;  
5,6 p<0.05). All comparisons are performed between particular indices of different study groups.  
 
 
5.5.2. Study II and III 
We compared the results of LPO and GSSG/GSH in the gut in five groups with 
the group of mice infected with S. Typhimurium and thereafter treated with 
ofloxacin and L. fermentum ME-3 mice as a reference group. The indices of 
oxidative stress, i.e. the level of LPO and the ratio of oxidised and reduced 
glutathione were the highest in mice challenged with S. Typhimurium.  
The ratio of oxidised and reduced glutathione decreased in the small 
intestine by combined ofloxacin and L. fermentum ME-3 treatment when 
compared to mice challenged with S. Typhimurium (p<0.005) (Fig. 8). 
Similarly, the addition of L. fermentum ME-3 to ofloxacin treatment reduced 
the LPO values when compared to mice infected with S. Typhimurium 
(p<0.005), while the corresponding values of PBS group were lower (p<0.005) 
(Fig. 9). 
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p<0.005
 
Figure 8. GSSG/GSH (range and median) in the gut of mice from study II and III. The 
numbers on x-axis indicate different mice groups. Gr 1 (n=17) mice received PBS by 
intragastric gavage. Gr 2 (n=12) study III mice were administered L. fermentum ME-3. 
Gr 3 mice (n=26) were challenged with S. Typhimurium. Gr 4 mice (n=19) were 
challenged with S. Typhimurium and treated with ofloxacin. Gr 5 mice (n=19) were 
challenged with S. Typhimurium and treated with ofloxacin and L. fermentum ME-3. Gr 
6 mice (n=13) received L. fermentum ME-3 after challenge with S. Typhimurium. The 
Kruskal-Wallis One-Way Analysis of Variance on Ranks.  
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Figure 9. LPO (range and median) in the gut of the mice from study II and III. The 
numbers on x-axis indicate different mice groups. Gr 1 (n=17) mice received PBS by 
intragastric gavage. Gr 2 (n=12) study III mice were administered L. fermentum ME-3. 
Gr 3 mice (n=26) were challenged with S. Typhimurium. Gr 4 mice (n=19) were 
challenged with S. Typhimurium and treated with ofloxacin. Gr 5 mice (n=19) were 
challenged with S. Typhimurium and treated with ofloxacin and L. fermentum ME-3. Gr 
6 mice (n=13) received L. fermentum ME-3 after challenge with S. Typhimurium. The 
Anova with Bonferroni correction was applied.  
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5.6. Immunological indices  
5.6.1. Profile of cytokines in the small intestine and  
liver of mice challenged with S.Typhimurium  
on Day 5 and Day 10 
The profile of cytokines was tested in study III. The values of pro-inflammatory 
cytokines INF-γ and TNF-α in the small intestine were the highest after 
inoculation with S. Typhimurium (Gr 1) at Day 10 (Table 5).  
To find the impact of combined treatment to the profile of cytokines, the 
mice from Gr 3 (mice challenged with S. Typhimurium and treated with 
ofloxacin and L. fermentum ME-3) were set as a reference to all mice groups 
challenged with S. Typhimurium. The addition of L. fermentum to ofloxacin 
treatment reduced the values of the tested pro-inflammatory cytokines: INF-γ in 
the the liver on both days (p=0.04, p=0.002, respectively), and TNF-α on both 
days (p=0.03, 0.04 in the liver and 0.02, 0.004 in the small intestine) when 
compared to Gr 1. The values of anti-inflammatory IL-10 in the liver increased 
on both experimental days when compared to mice challenged with S. 
Typhimurium Gr 1 (p=0.01, 0.005, respectively).  
The additive effect of the probiotic to ofloxacin was confirmed by the 
immunomodulatory response: decrease of the values of INF-γ and TNF-α on 
Day 5 in the liver (p=0.0007; p=0.02, respectively) when compared to Gr 2. 
The presence of typhoid nodules in the liver was associated with high values 
of pro-inflammatory INF-γ in the liver on both tested days (p=0.002 and 
p=0.039, respectively) (Table 6). The absence of typhoid nodules was 
associated with high IL-10 values in the liver on Day 10 (p=0.001). Moreover, 
the degree of necrosis of the typhoid nodules in the liver was associated with the 
increase of TNF-α in the small intestine (R2=0.18, p=0.002) in mice challenged 
with S. Typhimurium (data not shown).  
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Table 6. The median values and ranges of cytokines (pg/mg tissue) in liver in the 
presence /absence of liver typhoid nodules on Day 5 and Day 10 in mice challenged 
with S.Typhimurium.  
Indices 
Typhoid nodules No typhoid nodules 
p-values 
Day 5 (n=5) Day 10 (n=13) Day 5 (n=13) Day 10 (n=5) 
INF-γ  272 (223–533)a 113 (8–377) b 113 (22–30) a 26 (2–63) b 
a 0.002 
b 0.039 
TNF-α  138 (95–196) 74 (10–256) 116 (10–272) 126 (80–134) NS 
IL-10  113 (108–210) 178 (22–300) c 198 (66–315) 292 (238–422) c c 0.001 
Common letters indicate p- values. Mann-Whitney method was applied.  
 
 
5.6.2. Profile of cytokines in the small intestine and  
liver of mice administered L. fermentum ME-3and mice  
of control group on Day 5 and Day 10  
In non-infected mice the administration of L. fermentum ME-3 reduced the 
amount of pro-inflammatory cytokine TNF-α in the small intestine and liver on 
Day 5 (p=0.015, 0.002) and increased anti-inflammatory cytokine IL-10 in the 
small intestine (p=0.004) and liver on Day 5 (p=0.004) and Day 10 (p=0.014) as 
compared to control group mice (Fig. 10 and 11). The increase of INF-γ was 
detected on Days 5 and 10 (p=0.001, p<0.001) in the liver though no shifts were 
found in the gut. Further, the total number of lactobacilli in the small intestine 
of mice groups who were administered L. fermentum ME-3 was in a negative 
correlation (r=–0.422; p=0.039) with the values of INF-γ and in a positive 
correlation with IL-10 (r=0.551; p=0.005).  
 
 
45 
C ME-3 C ME-3 C ME-3
50
100
150
C
yt
ok
in
es
 in
 s
m
al
l i
nt
es
tin
e
pg
/m
g
tis
su
e
D5    D10             D5    D10             D5    D10 
INF-γ TNF-α IL-10    
a
a
b
b,c
c
 
Figure 10. The concentration of INF-γ, TNF-α and IL-10 (range and median) in the 
small intestine of uninfected mice: control C with PBS and probiotic L. fermentum  
ME-3 (ME-3) on Day 5 is marked with light green and Day 10 is marked with dark 
green. Common letters indicate statistically significant differences: a – p=0.015,  
b – p=0.004, c – p=0.017 
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Figure 11. The concentration of INF-γ, TNF-α and IL-10 (range and median) in the 
liver of uninfected mice: control C with PBS is shown with blue and probiotic L. 
fermentum ME-3 (ME-3) on Day 5 is marked with light green and Day 10 is marked 
with dark green. Common letters indicate statistically significant differences:  
a – p=0.001, b – p=0.026, c – p= 0.002, d – p=0.002, e – p=0.004; f – p=0.014 
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6. GENERAL DISCUSSION 
In our study the hypothesis concerning the additive value of probiotic 
Lactobacillus sp. to antimicrobial treatment was proved by the reduction of 
persistent Salmonella infection and the putative mechanisms behind it were 
assessed (Fig.12).  
The persistence of infection was studied in S. Typhimurium experimental 
murine infection model. Experimentally induced Salmonella Typhimurium 
infection in mice and rats is a widely used model for typhoid fever in humans. 
Pathogenetically it resembles the acute phase of typhoid fever caused by S. 
Typhi (Monack et al., 2004; Andrews-Polymenis et al., 2010). The human and 
rodent diseases are similar: the ileum is the main site of bacterial colonization 
and invasion, and there is a bacterial proliferation and response with granulomas 
within the reticuloendothelial system (Naughton et al., 1996). 
 
 
Figure 12. Summary of the detected microbiological, morphological, biochemical, and 
immunological effects. Arrows indicate detected effects of the tested microbes: S. 
Typhimurium, and L. fermentum ME-3.  
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6.1. Role of immunological and oxidative stress 
indices on the development of persisting Salmonella 
Typhimurium infection 
The persistence of the infection was proved by the presence of granulomas in 
the liver and spleen on Day 5 and 10. It has been shown earlier that the majority 
of S. Typhimurium bacteria are localized within phagocytes in the granulomas 
in the liver or spleen (Clare et al., 2003).  
In order to characterize the impact of oxidative stress on persistent infection 
the following indices were detected: lipid peroxidation and glutathione redox 
ratio, iron concentration and saturation of iron. Our results indicated the 
presence of OxS in the developed persistent infection.  
For detection of immunological impact we chose the pro-inflammatory 
cytokines INF-γ, TNF-α, and the anti-inflammatory IL-10. These cytokines 
have been previously studied in the persistence of the infection due to S. 
enterica serovar Typhimurium in mice (Sashinami et al., 2006). The expression 
of pro-inflammatory cytokines is associated with the release of ROS and 
disruption of the total antioxidant response pathways (Murata et al., 2002). This 
accordance was also found in our studies. The increased values of pro-
inflammatory cytokines in infected mice were accompanied by the increased 
oxidative stress indicating values of LPO, GSSG/GSH, and Fe content, and low 
TAA in the small intestine. 
In the initial stage of inflammation after invasion of S. Typhimurium, the 
pro-inflammatory cytokines (INF-γ, IL-1, IL-6, IL-12, and IL-18) are activated 
(Mittrucker et al., 2000). Similarly, our data depicted the increased values of the 
pro-inflammatory cytokine INF-γ in the small intestine and in the liver on Day 5 
of infection and persistence until Day 10. Moreover, the high values of INF-γ in 
the liver correlated with the presence of typhoid nodules. 
TNF-α is involved in the formation and persistence of granulomas as well as 
in the regulation of NADPH oxidase-mediated killing of Salmonella 
Typhimurium by macrophages (Beal et al., 2006). In our study III, the increase 
of the values of TNF-α in the gut seemingly reflect the inflammatory damage of 
intestinal mucosa in the small intestine, enabling the invasion of S. 
Typhimurium into the blood and organs. Also, on Day 10 of S. Typhimurium 
infection we found the association between the degree of necrosis of typhoid 
nodules in the liver and the increase in TNF-α in the small intestine in mice 
challenged with S. Typhimurium. 
It has been shown earlier that the anti-inflammatory and regulatory cytokine 
IL-10 inhibits the production of reactive oxygen and reactive nitrogen species, 
and intermediates when macrophages are activated by INF-γ. Namely, it inhibits 
TNF-α and IL-12 production by macrophages and their stimulatory effect of 
INF-γ production by natural killer cells (Sashinami et al., 2006). We found that 
the absence of typhoid nodules was associated with high IL-10 values in the 
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liver on Day 10. We suggest that the high values of IL-10 may protract the 
development of liver granulomas and development of persistent infection.  
 
 
6.2. The impact of lactobacilli on immunological  
and oxidative stress indicative indices  
of gut without and with infection 
The immunomodulatory activity of probiotics is considered strain-specific and 
cannot be extrapolated to other genera or species (Dogi et al., 2008). Similar 
trends were obtained in our study. We found that L. fermentum ME-3 increased 
the values of IL-10 in the mucosa of the small intestine and liver. When L. 
acidophilus E-1 and L. fermentum ME-3 were administered to mice in study I, 
the hyperplasia of lymph patches in small intestine was detected indicating the 
increased barrier function of gut mucosa. However, the counts of intestinal 
lactobacilli did not increase. The third tested probiotic L. plantarum Inducia 
also induced hyperplasia of lymph patches and after a longer one month period 
of administration the total counts of lactobacilli increased. Thus, the effect of 
probiotic bacteria on immunemodulation is beside strain-specificity also tightly 
bound to the duration of administration.  
The effects of probiotics on the immune system are exerted through effects 
on antigen-presenting cells, such as macrophages and dendritic cells. Among 
the cytokines that are produced by these cells, particular attention has been paid 
to the probiotic control of the production of IL-12, which plays a central role in 
the activation of innate immunity, and IL-10, which, in contrast, acts to inhibit 
the inflammatory response (Foligne et al., 2007). 
In addition, in vitro studies have revealed that due to their effects on APCs, 
probiotics may affect the differentiation into Th cell subsets and the production 
of cytokines therein. It has been revealed that lactobacilli, such as Lactobacillus 
casei Shirota or Lactobacillus reuteri ATCC 23272, induce Th1 cells via the 
production of IL-12 generated by macrophages, and DCs (Mohamadzadeh and 
Klaenhammer, 2008) and Bifidobacterium bifidum W23 and Bifidobacterium 
longum W52 inhibit the production of cytokines generated by Th2 cells via the 
production of IL-10 generated by monocytes (Maassen et al., 2000). The 
probiotic L. casei has considerable potential to induce IL-12 production and 
promote Th1 cell development (Chiba et al., 2010).  
Previous ex vivo experiments have reported the ability of L. casei and of L. 
bulgaricus to downregulate TNF-α production in colonic explants from patients 
with Crohn’s disease, thus supporting the possibilities for their future develop-
ment in IBD therapy (Peran et al., 2005). The suppression of this cytokine was 
found also in our model of systemic salmonella infection treated with probiotic 
L. fermentum ME-3.  
Antioxidative and antagonistic activity of intestinal lactobacilli varies 
between species and strains (Achuthan, 2012). Thus, it can also be related to 
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their fermentation type (Annuk et al., 2003). For instance, the production of 
succinic acid by heterofermentative L. fermentum species supports the antioxi-
dative effects (Stsepetova, 2011). Moreover, antioxidative Lactobacillus could 
modulate a redox state in colonic fermentation system, which is related to their 
free radical–scavenging ability or antibacterial effect (Sun et al., 2010). The L. 
fermentum ME-3 strain we applied in our studies is characterized by a complete 
glutathione system: synthesis, uptake and redox turnover ability (Kullisaar et 
al., 2010), and high TAA and TAS values of intact cells and lysates (Mikelsaar 
and Zilmer, 2009). At the same time, the antimicrobial effect against 
gastroenteritis causing S. Typhimurium, S. sonnei, and uropathogenic E. coli 
(Hutt et al., 2006) is accompanied with the production of H2O2 (Mikelsaar, 
2007). The antioxidative properties of L. fermentum ME-3 depend on the 
growth phase and environmental conditions (aerobic, anaerobic). The TAA 
values and production of H2O2 depends on the growth phase of L. fermentum 
ME-3. In the exponential growth phase the production of H2O2 increased and 
TAA decreased, in stationary phase H2O2 concentration remained stable and 
TAA values were at the highest level (Kullisaar et al., 2010).  
In our study I we applied two different lactobacilli of human intestinal 
origin: namely, L. acidophilus E-1 and L. fermentum ME-3. The administration 
of these lactobacilli decreased the total count of lactobacilli in the terminal 
ileum of mice; however, hyperplasia of lymph nodes was registered in the group 
of mice receiving both aforementioned lactobacilli. At the same time, the 
antioxidative potential of L. fermentum ME-3 influenced the gut mucosa by the 
reduction of iron level, and lipid peroxidation with simultaneous increase of 
total antioxidative activity and glutathione redox value. One explanation is 
probably the complete glutathione system of L. fermentum ME-3: synthesis, 
uptake and redox turnover ability (Kullisaar et al., 2010). Antioxidative 
Lactobacillus could modulate redox state in gut fermentation systems, which is 
related to their free radical–scavenging ability or antibacterial effect (Sun et al., 
2010). DeLeBlanc et al 2010 determined the preventive and therapeutic effect 
of L. casei CRL 431 in protection against murine Salmonella Typhimurium 
infection. The results obtained demonstrated that 7 days of L. casei CRL 431 
administration before infection decreased the severity of the infection with 
Salmonella Typhimurium due to the influence on the cells of the innate and 
adaptive immune response. Namely, the neutrophil infiltration decreased; the 
macrophage phagocytic activity was activated in different sites, and the number 
of IgA+cells in the lamina propria of the small intestine increased and 
correlated well with the increased release of s-IgA specific antibodies against 
the pathogen in the intestinal fluids (de LeBlanc and Ade, 2010). 
Mileti et al 2009 compared the immunological properties of Lactobacillus 
plantarum NCIMB8826, L. rhamnosus GG (LGG), and L. paracasei B21060 
against pathogenic Salmonella Typhimurium (SL1344) and found that the three 
strains exhibited different abilities to induce inflammatory cytokine production 
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by DCs with L. plantarum being the most effective followed by LGG and L. pa-
racasei (Mileti et al., 2009). 
L. fermentum ACA-DC 179 was a strong inducer of the anti-inflammatory 
regulatory cytokine IL-10 (Zoumpopoulou et al., 2008). Additionally, when L. 
fermentum ACA-DC 179 was used in a Salmonella-infected mouse model, its 
administration revealed an in vivo anti-Salmonella activity. These results 
coincide with our results as L. fermentum ME-3 caused significant increase of 
IL-10 in study III. 
 
 
6.3. Impact of the combination of lactobacilli and 
antibiotic on S. Typhimurium infection. 
In our experimental infection, application of ofloxacin could not prevent the 
formation of granulomas in the liver and spleen of mice infected with S. 
Typhimurium, despite the fact that our applied S. Typhimurium was susceptible 
to ofloxacin. However, the antioxidative probiotic L. fermentum ME-3 combi-
ned with ofloxacin enhanced the eradication of experimental S. Typhimurium 
infection. Salmonella Typhimurium was eradicated from the blood, ileum and 
liver, the number of animals with liver and spleen granulomas decreased and the 
value of lipid peroxides in the ileum mucosa reduced. Moreover, we found that 
higher total counts of intestinal lactobacilli were associated with the absence of 
liver granulomas. The immunological response included a reduction of pro-
inflammatory cytokines INF-γ, TNF-α and an increase in anti-inflammatory 
cytokine IL-10 in the livers of mice without typhoid nodules.  
Several lactobacilli have proved efficacy in different diseases in experi-
mental studies. Recently, Ashara and his colleagues have found that after oral 
infection with S. Typhimurium DT104 during fosfomycin treatment continuous 
administration of Lactobacillus casei Shirota inhibited the infection due to the 
increased concentration of organic acids and maintenance of lower pH in the 
intestine (Ashara et al., 2010).  
The probiotic bacteria Lactobacillus plantarum 299v given daily enterally to 
critically ill patients on broad-spectrum antibiotic therapy survived the passage 
through the gastrointestinal tract and colonized the rectal mucosa. Their 
administration increased the number of lactobacilli and reduced the number of 
Enterobacteriaceae. The authors concluded that L. plantarum 299v may have 
an effect on the mucosal barrier or even have a positive impact on the immune 
system (Klarin et al., 2005). This finding coincides with our results of 
hyperplasia of the lymph nodes in the gut. 
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7. LIMITATIONS OF THE STUDY 
The thesis has some limitations. First, we applied culture-based methods to 
estimate the total count of lactobacilli in the gut. Thus, we could not 
differentiate between the indigenous lactobacilli and the count of particular 
administered Lactobacillus strains.  
Second, as we did not aim to detect the impact of ofloxacin, the group 
receiving only ofloxacin without salmonella infection was not included. In order 
to exclude its impact on biochemical and immunological indices this group 
would have been helpful.  
Third, in study IV, the number of mice was too low to demonstrate a 
statistically significant difference though a 3.5 to 6 times increase of lymphatic 
nodules by administration of probiotic L. plantarum Inducia was apparent.  
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8. CONCLUSIONS 
1.  The developed persistent S.Typhimurium infection is characterized by 
presence of viable S. Typhimurium in the blood and organs. The presence of 
granulomas in the liver and spleen is accompanied by increased levels of 
OxS indices (LPO, GSSG/GSH) and increased values of pro-inflammatory 
cytokines (TNF-α and INF-γ) in the gut and liver. 
 
2.  The application of two lactobacilli of human origin, L. fermentum ME-3 
with high antimicrobial and antioxidative potential in vitro and L. aci-
dophilus E-1 for 10 days, neither eradicated S.Typhimurium nor prevented 
the developement of granulomas in the liver. An improvement of gut 
mucosal barrier due to decreased values of lipid peroxides and glutathione 
redox ratio was still detected. 
 
3.  The administration of cheese containing Lactobacillus plantarum Inducia for 
one month increased the count of intestinal lactobacilli and hyperplasia of 
the lymphatic follicles in the ileum and colon of healthy mice indicating 
immunomodulation of the intestinal mucosa by probiotic lactobacilli. 
 
4.  The combined treatment of ofloxacin and L. fermentum ME-3 increased the 
eradication of S. Typhimurium and reduced the prevalence of granulomas in 
the liver and was accompanied by decreased OxS indices in persistent 
typhoid model of mice. The higher total count of lactobacilli in the gut was 
associated with the absence of liver granulomas. 
 
5.  The effect of administration of combined treatment of ofloxacin and L. 
fermentum ME-3 in persistent Salmonella Typhimurium infection is 
demonstrated by the immunomodulation in the gut and liver. On Day 10 
after challenge with S. Typhimurium, the reduction of pro-inflammatory 
cytokine INF-γ in the liver was accompanied with an increase of anti-
inflammatory cytokine IL-10 in the mice without typhoid nodules in the 
liver.  
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10. SUMMARY IN ESTONIAN 
Probiootiliste laktobatsillide toime eksperimentaalsele 
persisteerivale salmonella infektsioonile: mikrobioloogilised, 
morfoloogilised, biokeemilised ja immunoloogilised efektid 
Salmonella enterica serovar Typhi nakkus kulgeb generaliseerunud infektsioo-
nina, mille suremus adekvaatse ravita on kõrge. Ka paranemisel võib kujuneda 
oluliseks probleemiks püsiva e. persisteeriva infektsiooni teke, mis kulgeb kas 
kroonilise infektsioonina, korduvate ägenemistega või sümptomivaba kand-
lusena. Viimatinimetatu on nakkuse leviku tõttu ohuks ümbritsevatele inimes-
tele. Ajaloost on teada isik, kes nakatas 57 inimest, olles Salmonella Typhi 
kandja ilma haigunähtudeta. S. Typhi kandjatel on risk haigestuda maksa ja 
sapiteede kasvajatesse.  
Kuigi Salmonella Typhi infektsiooni esinemissagedus Eestis on madal, on 
arengumaades endiselt raskusi selle infektsiooni profülaktika ja raviga, ohus-
tades ka reisijaid neisse maadesse. S. Typhi tekitab kõhutüüfust ainult inimestel, 
seetõttu kasutatakse selle generaliseerunud infektsiooni uurimismudelina liini-
hiirte nakatamist Salmonella enterica serovar Typhimurium tüvedega.  
Laktobatsillid e. piimhappe bakterid kuuluvad inimese soole normaalsesse 
mikroobikooslusesse. Probiootikumid on rahvusvahelise määratluse järgi elusad 
mikroobid, mis küllaldases annuses mõjuvad tervisele kasulikult. Probiooti-
kumide toimemehhanismidena on kirjeldatud otsest mõju patogeenidele tänu 
vesinikperoksiidi, piimhappe, bakteriotsiinide tekkele, konkurentsi toitainetele, 
adhesiooni ning immuunsuse modulatsiooni. Mitmetel probiootilistel laktobat-
sillidel on täheldatud antagonistlikku toimet soolepatogeenidele, sh. salmonella-
dele, kuid puudub arusaam täpsematest toimemehhanismidest, eeskätt per-
sisteerimisele kalduvate infektsioonide puhul.  
 
 
Uurimistöö eesmärgid 
Selgitada erinevate laktobatsillide võimalikke toimemehhanisme salmonellade 
persisteeriva infektsiooni suhtes ja teha kindlaks probiootilise Lactobacillus 
plantarum Inducia DSM 21379 mõju soole immuunsüsteemile.  
Selleks püstitati järgnevad ülesanded: 
1. Määrata S. Typhimuriumiga nakatatud hiirtel S. Typhimurium veres, maksas, 
põrnas ja sooles ning laktobatsillide üldhulk sooles; granuloomide olemasolu 
maksas ja põrnas ning oksüdatiivse stressiga seotud näitajad (LPO, 
GSSG/GSH) ja tsütokiinid (TNF-α, INF-γ ning IL-10). 
2. Teha kindlaks inimpäritolu laktobatsillide Lactobacillus fermentum ME-3 ja 
Lactobacillus acidophilus E1 toime persisteerivale Salmonella Typhimurium 
infektsioonile hiire mudelis, määrates salmonella ja laktobatsillide üldhulga, 
samuti oksüdatiivse stressiga seotud näitajad ning maksa, põrna ja soole 
histoloogilised muutused.  
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3. Selgitada Lactobacillus plantarum Inducia toimet soole laktobatsillide 
üldhulgale ja soole limaskesta barjäärile tervetel hiirtel peale 30-päevast L. 
plantarum Inducia’t sisaldava juustu söötmist.  
4. Hinnata, kas L. fermentum ME-3 lisamine ofloksatsiin ravile mõjutab S. 
Typhimuriumi elulemust veres, maksas, põrnas ja sooles; maksa ja põrna 
granuloomide teket ning oksüdatiivse stressi näitajaid sooles.  
5. Määrata pro- ja antiinflammatoorsete tsütokiinide tase sooles ja maksas L. 
fermentum ME-3 lisamisel ofloksatsiinravile persisteeriva S.Typhimurium 
infektsiooni korral hiirel. 
 
 
Materjal ja meetodid  
Salmonella Typhimuriumi ja laktobatsillide mikrobioloogilisteks uuringuteks 
kasutasime erinevaid söötmeid ja kasvutingimusi. Külvid tehti verest, maksast, 
põrnast, peen- ja jämesoolest.  
Histoloogilised näitajad määrasime koostöös TÜ Patoloogilise anatoomia ja 
Kohtumeditsiini instituudiga. Katse lõpus loomad lahati, koe lõigud maksast, 
põrnast ja peen-ning jämesoolest värviti hematoksüliin eosiiniga, seejärel 
mikroskopeeriti ja hinnati destruktiivseid ja põletikunäitajad.  
Oksüdatiivse stressi näitajad ja tsütokiinid määrasime koostöös TÜ Bio-
keemia instituudiga. Soole limaskestast ja maksast võetud proovidest analüüsiti 
oksüdatiivse stressi näitajaid: LPO, GSSG/GSH, raua hulk ning pro- ja 
antiinflammatoorsed tsütokiinid INF-γ, TNF- α ja IL-10.  
 
 
Järeldused 
1. Persisteerivat S.Typhimurium infektsiooni iseloomustas eluvõimeliste S. 
Typhimurium bakterite esinemine veres ja uuritud organites; granuloomide 
esinemine maksas ja põrnas, kõrgenenud oksüdatiivse stressi näitajad (LPO, 
GSSG/GSH) ja proinflammatoorsed tsütokiinid (TNF-α and INF-γ) sooles ja 
maksas.  
2. Inimpäritolu laktobatsilli in vitro kõrgete antimikroobsete ja antioksü-
dantsete omadustega L. fermentum ME-3 ja L. acidophilus E-1 tüve koos 
manustamine 10 päeva jooksul ei eemaldanud S.Typhimuriumi. Siiski leiti 
soole limaskesta barjäärfunktsiooni paranemine oksüdatiivse stressi lange-
tamise tõttu tänu lipiidperoksiidide ning oksüdeeritud ja redutseeritud 
glutatiooni suhte vähenemisele. 
3. Lactobacillus plantarum Induciat sisaldava juustu manustamine ühe kuu 
jooksul põhjustas laktobatsillide hulga tõusu ning peen- ja jämesoole lümfi-
folliikulite hüperplaasia nakatamata hiirtel, mis näitab soole kaitsevõime 
paranemist. 
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4. Kombineeritud ravi ofloksatsiini ja L. fermentum ME-3-ga suurendas Salmo-
nella Typhimuriumi eradikatsiooni, vähendas granuloome maksas ja oksü-
datiivse stressi näitajaid persisteeriva S. Typhimurium infektsiooni hire 
mudelis. Leidsime, et sooles laktobatsillide kõrgema üldhulga korral puudu-
vad maksas granuloomid. 
5. Kombineeritud ravi ofloksatsiini ja L. fermentum ME-3-ga soodustas 
immuunvastust sooles ja maksas. 10 päeva pärast vähenes proinflamma-
toorne tsütokiin INF-γ maksas ja sooles ja suurenes antiinflamatoorse  
IL-10 hulk maksas ilma granuloomideta hiirtel. 
 
Seega näitavad meie uurimistulemused mikrobioloogilist, morfoloogilist, bio-
keemilist ja immunoloogilist efekti kasutades antibiootikumi (ofloksatsiin) ja 
probiootilise laktobatsilli (Lactobacillus fermentum ME-3) kombineeritud ravi 
persisteeriva S. Typhimurium infektsiooni korral hiire mudelis. 
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